Moloney Securities Asset Management LLC Invests $1.13 Million in Stryker Co. (NYSE:SYK)

Moloney Securities Asset Management LLC purchased a new stake in Stryker Co. (NYSE:SYK - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,137 shares of the medical technology company's stock, valued at approximately $1,133,000.

Other institutional investors also recently modified their holdings of the company. Centennial Bank AR grew its position in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after purchasing an additional 48 shares in the last quarter. Central Pacific Bank Trust Division purchased a new position in Stryker during the 1st quarter worth approximately $39,000. HBW Advisory Services LLC purchased a new position in Stryker during the 3rd quarter worth approximately $42,000. Grove Bank & Trust grew its holdings in shares of Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company's stock valued at $44,000 after acquiring an additional 56 shares in the last quarter. Finally, DT Investment Partners LLC grew its holdings in shares of Stryker by 114.3% during the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company's stock valued at $49,000 after acquiring an additional 72 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Stryker stock traded down $0.84 during trading hours on Wednesday, hitting $369.02. 1,366,185 shares of the stock were exchanged, compared to its average volume of 1,257,470. Stryker Co. has a 12 month low of $266.93 and a 12 month high of $376.04. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The business's 50-day moving average is $360.66 and its two-hundred day moving average is $344.95. The stock has a market capitalization of $140.68 billion, a P/E ratio of 39.55, a P/E/G ratio of 2.77 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion for the quarter, compared to analysts' expectations of $5.37 billion. During the same period in the prior year, the firm earned $2.46 earnings per share. Stryker's revenue was up 11.9% compared to the same quarter last year. Equities research analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Canaccord Genuity Group boosted their price target on shares of Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Stifel Nicolaus lowered their price target on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Piper Sandler restated an "overweight" rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. BTIG Research lifted their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Finally, Citigroup lifted their price objective on shares of Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $393.65.

Insider Activity at Stryker

In related news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,068 shares of company stock worth $3,693,972 over the last ninety days. Company insiders own 5.50% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.